.png){kind=icon}
返回
Fingolimod for Multiple Sclerosis
.png){kind=icon}
PRE
AI
DOI：10.1056/NEJMct1101691.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
A 37-year-old man with multiple sclerosis was evaluated for consideration of oral immunotherapy. Six years earlier, he had reported acute monocular visual disturbance. The diagnosis of multiple sclerosis was subsequently confirmed by means of examination of cerebrospinal fluid, which revealed an increased IgG index and oligoclonal banding, and by abnormal results on magnetic resonance imaging (MRI). There was no family history of multiple sclerosis. Daily injections of glatiramer acetate were initiated at the time of diagnosis, but two consecutive annual brain MRI scans revealed substantial disease activity. He was then switched to interferon beta therapy, but this treatment was discontinued after the patient had two episodes of acute neurologic worsening. Monthly natalizumab therapy was then considered, but a test for JC virus antibodies was positive. Neurologic examination showed disk pallor and visual acuity of 20/40 in the right eye, partial internuclear ophthalmoplegia, wide-based gait, and posterior column deficits in both legs. The patient was referred to a specialist in multiple sclerosis for consideration of oral fingolimod therapy.
Keyword:
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
SPHINGOSINE 1-PHOSPHATE
ORAL FINGOLIMOD
INTRAMUSCULAR INTERFERON
NATURAL-HISTORY
T-CELLS
FTY720
SURVIVAL
PROLIFERATION
NATALIZUMAB
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
78.5
论文数:
2.7W
被引数:
39.7W
机构
引用论文
Trends in survival and cause of death in Danish patients with multiple sclerosis丹麦多发性硬化症患者的生存趋势和死亡原因.png)
BRAIN
OAAI
BRAINIF11.7
OAAI分享收藏A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis口服芬戈莫德治疗复发性多发性硬化症的安慰剂对照试验
OAAI
OAAI分享收藏The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptorsFASEB JOURNAL
FASEB JOURNALIF4.2
PREAI
分享收藏
查看更多内容